Benjamin Stone is chief business officer at AnaptysBio, a clinical-stage biotechnology company focused on innovative immunology therapeutics, where he has built an integrated strategic function spanning corporate strategy, new product planning, corporate development and program management. Known for his patient-centered mindset shaped by his experiences as a pediatric epilepsy patient, Stone is recognized as a dynamic leader committed to pursuing the development of novel, practice-changing, disease-modifying therapies over incremental improvements on existing drugs.
As CBO, Stone has led a critical portfolio transformation, helping to focus the company’s development efforts on immune cell modulators while broadening the scope of development beyond dermatology to diseases where the novel biology of Anaptys’ pipeline molecules overlaps with substantial unmet need. In addition to sourcing targets from the company’s discovery engine, he has championed the acquisition of new assets and completed out-licensing and royalty monetization transactions to support pipeline sustainability.
Previously, Stone was an operating principal at Two River, co-founding and serving in interim management roles at multiple portfolio companies. Prior to Two River, he led corporate strategy at Spark Therapeutics, where he was part of the team that secured FDA approval for the first gene therapy for a genetic disease. Stone also facilitated Spark’s $4.8 billion acquisition by Roche. Prior to Spark, he was a member of the Healthcare Investment Banking Group at Credit Suisse. He earned a Bachelor of Science in finance from the Wharton School of the University of Pennsylvania and a Bachelor of Arts in international studies from the University of Pennsylvania.